1 BTC
=
- USD
PERRIGO COMPANY PLC
As of May 30, 2026 at 24:05 UTC
Chart
About PERRIGO COMPANY PLC
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Market Statistics
Trading Metrics
How to Buy PRGO
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy PRGO
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesPerrigo Company plc announced that its Board of Directors has approved a quarterly dividend of $0.29 per share ($1.16 annualized). The dividend is payable on June 16, 2026, to shareholders of record on May 29, 2026.
The article examines three high-yielding healthcare stocks: Perrigo (9.6% yield) faces growth slowdown and profitability pressure despite a 23-year dividend streak; Healthpeak Properties (7.1% yield) offers potential upside through its Janus Living spinoff; Medical Properties Trust (6.8% yield) has stabilized after significant dividend cuts due to tenant bankruptcies but faces ongoing debt maturities.
The article highlights five small-cap stocks offering high dividend yields (6.6%-11%) that remain undervalued despite strong 2026 performance. The author recommends regional banks and energy companies as income-generating opportunities, though warns of risks including economic sensitivity and potential dividend sustainability concerns.
Good Start® | Dr. Brown's™ infant formula has been named 'Baby Food Product of the Year' at the 2025 Baby Innovation Awards. The partnership combines Good Start's 50+ year heritage with Dr. Brown's pediatrician-recommended bottles to offer tolerance-focused infant formulas including Soothe Pro®, Gentle Pro®, and Soy-ease Pro® variants designed to address common feeding challenges like fussiness, gas, and digestive issues.
The global scar treatment market is projected to grow from USD 26.60 billion in 2025 to USD 56.30 billion by 2033, with a CAGR of 9.91%. Growth is driven by increasing awareness of advanced cosmetic and reconstructive procedures, rising prevalence of acne, surgical, and traumatic scars, and technological advancements in minimally invasive treatments. The U.S. market alone is expected to reach USD 17.69 billion by 2033.
